Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antiarrhythmic drugs.

P F Nestico1, J Morganroth, L N Horowitz

  • 1Likoff Cardiovascular Institute, Hahnemann University, Philadelphia.

Drugs
|March 1, 1988
PubMed
Summary

New antiarrhythmic drugs offer improved options for treating ventricular arrhythmias. This review compares new and conventional agents to guide clinical selection for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor.

Journal of clinical pharmacology·2011
Same author

Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.

Clinical pharmacology and therapeutics·2010
Same author

Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).

Clinical pharmacology and therapeutics·2009
Same author

Cardiac repolarization and the safety of new drugs defined by electrocardiography.

Clinical pharmacology and therapeutics·2006
Same author

Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs.

Ernst Schering Research Foundation workshop·2006
Same author

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.

British journal of clinical pharmacology·2001

Area of Science:

  • Pharmacology
  • Cardiology
  • Clinical Medicine

Background:

  • Ventricular arrhythmias present ongoing treatment challenges.
  • Advances in antiarrhythmic drug development offer new therapeutic avenues.

Purpose of the Study:

  • To review and compare new and conventional antiarrhythmic drugs.
  • To provide a basis for selecting drug therapy for ventricular arrhythmias.

Main Methods:

  • Literature review of electrophysiological, pharmacokinetic, and safety data.
  • Comparison of new agents (mexiletine, tocainide, flecainide, etc.) with conventional agents (quinidine, lidocaine, etc.).

Main Results:

  • New agents possess diverse pharmacokinetic and electrophysiological profiles.
  • Data on efficacy and safety are summarized for informed comparison.

Conclusions:

  • Clinicians can use this data to develop algorithms for selecting antiarrhythmic therapy.
  • Rational drug selection can improve the management of ventricular arrhythmias.

Related Experiment Videos